Drug formulations in the market are changing with the share of subcutaneous administration over intravenous infusion increasing. Subcutaneous administration is seen to be the preferred approach both by patients and healthcare providers.
For subcutaneous injections, smaller volumes are required, and biological drugs must be prepared at higher concentrations. This is the case for mAbs that are used to treat various cancer and autoimmune diseases. Therefore, high-concentration mAbs are becoming more prevalent in the market. As the drug concentration increases towards the end of product manufacture, obtaining as much product as possible during final filtration stages becomes imperative.
We have developed Cytiva Supor™ Prime sterilizing grade membrane filters specifically to offer high mAb transmission performance and to minimize any impact of the drug critical quality attributes (CQAs).
This application note presents data on product transmission through the membrane for a Supor™ Prime membrane filter compared to other sterilizing grade filter membranes with two drug products, trastuzumab, and rituximab.
